BioMedNewsBreaks

WednesdayJan 15, 2025 2:52 pm

BioMedNewsBreaks — Astiva Health Achieves Remarkable 188% Membership Growth

Astiva, a leader in culturally responsive health care solutions, today announced a significant 188% growth in membership, increasing to 30,257 members as of January 2025 (up from 10,500 in January 2024). The milestone highlights Astiva’s position as a trusted provider of innovative health care tailored to diverse communities. “Growing from 10,000 to over 30,000 members reflects the trust and confidence our communities have placed in Astiva Health,” said Dr. Tri T. Nguyen, co-founder and CEO. “This achievement validates our commitment to delivering culturally sensitive health care solutions that meet the unique needs of our members. We are excited to build…

Continue Reading

WednesdayJan 15, 2025 8:15 am

BioMedNewsBreaks – HealthLynked Corp. Names Jeremy Daniel as Chief Financial Officer

HealthLynked (OTCQB: HLYK) a provider of healthcare technology solutions, has appointed Jeremy Daniel as its new Chief Financial Officer, effective immediately. With over 20 years of experience in healthcare, biotechnology, and finance, Daniel brings expertise in financial management, strategic planning, and organizational growth. Previously CFO at Innoveren Scientific, he has a strong track record in fundraising, mergers, and acquisitions, having raised over $100 million in funding. CEO Michael Dent, M.D., highlighted Daniel's alignment with HealthLynked's mission to innovate and expand its healthcare technology solutions. Daniel, a CPA and Xavier University MBA graduate, expressed enthusiasm for advancing the company's financial strategies…

Continue Reading

TuesdayJan 14, 2025 12:45 pm

BioMedNewsBreaks – Adageis Featured in BioMedWire Podcast

Adageis was featured in the latest episode of the BioMedWire Podcast, as part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Shane Speirs, CEO of Adageis, joined the program to provide an introduction to the company’s business model. “Healthcare is a complicated place, and navigating the system is extremely difficult for patients. On the healthcare delivery side, it's also tough. Classically, there have been different reimbursement methods for healthcare services in the United States, but many agree the future is value-based care,” Speirs explained. “What Adageis does is provide a simple solution to healthcare organizations…

Continue Reading

TuesdayJan 14, 2025 10:34 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, has received a U.S. patent for methods using buntanetap to treat and prevent acute brain and nerve injuries. The patent, issued on Jan. 2, 2025 (US-2025-0000846-A1), covers buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes in conditions such as stroke, ischemia, traumatic brain injury, and micro infarcts. Already patented in the EU, Japan, and globally, this approval enhances Annovis’ intellectual property portfolio. CEO Maria Maccecchini, Ph.D., emphasized buntanetap's potential to protect and restore neuronal health, expanding its applications beyond Alzheimer’s and Parkinson’s disease. To view the full press release,…

Continue Reading

TuesdayJan 14, 2025 8:45 am

BioMedNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company focused on neurological disorders, has received a Notification to Grant Patent Right for its Chinese invention patent application (No: 2020800553323). The patent covers compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, including autism, using a novel intranasal suramin formulation. CEO Howard Weisman highlighted this as a historic milestone, marking the first intellectual property protection for suramin in over a century. PaxMedica plans to pursue similar protections in additional jurisdictions, including the United States. To view the full press release, visit https://ibn.fm/DW1iE About PaxMedica Inc. PaxMedica is a forward-looking,…

Continue Reading

TuesdayJan 14, 2025 7:35 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites," has been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting, April 25-30, 2025, in Chicago. The presentation will highlight Calidi’s proprietary RTNova systemic platform, which leverages a novel vaccinia virus strain enveloped with a human cell membrane to overcome immune system elimination, enabling targeted delivery to multiple metastatic tumor sites. This innovative approach aims to address treatment challenges in advanced metastatic cancers, such as lung cancer, where…

Continue Reading

MondayJan 13, 2025 2:59 pm

BioMedNewsBreaks — Adageis’s Platform Empowering Organizations to Adjust to New Risk-Scoring Dynamics

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is in support of the Centers for Medicare and Medicaid Services’ (“CMS”) switching from the V24 to the V28 upgrade of the Hierarchical Condition Categories (“HCC”) model. “The transition from CMS-HCC V24 to V28 reflects a critical update to the risk adjustment model used in Medicare Advantage… The more precise structure enhances diagnostic specificity, allowing for better patient categorization. This change supports value-based care by tying payments more closely to actual patient needs,” reads a recent article. “The CMS-HCC transition aligns closely with Adageis’s mission of…

Continue Reading

MondayJan 13, 2025 7:30 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and expenses. The offering, exclusively placed by Ladenburg Thalmann & Co. Inc., is set to close on or around Jan. 10, 2025, subject to customary conditions. Proceeds will support working capital and general corporate purposes. The shares are offered under an effective Form S-3 registration statement, with a final prospectus available on the SEC’s website or through Ladenburg Thalmann. To view…

Continue Reading

FridayJan 10, 2025 9:41 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants in a public offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. The offering's size and terms depend on market conditions and are yet to be finalized. Proceeds will support working capital and general corporate purposes. The securities will be offered under an effective shelf registration statement filed with the SEC, and interested parties can access the preliminary prospectus and accompanying documents via the SEC website or through Ladenburg Thalmann's Prospectus…

Continue Reading

WednesdayJan 08, 2025 2:29 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

Continue Reading